Veliparib After Chemo Improves Outcomes for BRCA+ HER2- MBC

Moderators

Have you been diagnosed with metastatic HER2-negative breast cancer with a BRCA1 or BRCA2 mutation? A study found that people with this type of cancer treated with the experimental medicine veliparib and chemotherapy lived slightly longer without the cancer growing if they stayed on veliparib after stopping chemo, as long as they stopped chemo for reasons other than the cancer growing.

Read: Veliparib Maintenance After Chemo Slightly Improves Outcomes for Metastatic HER2-Negative Breast Cancer With BRCA Mutations